Thursday, Mar 1, 2001

Genentech Names Robert Garnick Senior Vice President, Regulatory, Quality And Compliance

South San Francisco, Calif. -- March 1, 2001 --

Genentech, Inc. (NYSE: DNA) today announced the promotion of Robert Garnick, Ph.D., to senior vice president, Regulatory, Quality and Compliance. Garnick reports to Susan D. Hellmann, M.D., M.P.H., executive vice president, Development and Product Operations, and chief medical officer.

"Iim confident that with Rob's 16 years of experience working in Genentech's regulated environment, we will be able to further integrate our best practices in the regulated aspects of our business including drug development, commercial production, and promotional and labeling compliance," said Hellmann.

Garnick, 51, joined Genentech in 1984 as manager of Quality Control. After a series of promotions in the Quality group, he became vice president of Quality in 1994. In 1997, he was named vice president of Regulatory Affairs. Garnick has made a number of important contributions by providing leadership for these departments during a period that included multiple product approvals and substantial growth for the company.

Prior to joining Genentech, Garnick was at Armour Pharmaceutical Company and Merrell National Laboratories.

Garnick holds a Bachelor of Science degree in chemistry from Rutgers University and a doctorate in organic chemistry/natural products from Northeastern University.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved products of biotechnology stem from Genentech science. Genentech markets nine products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #